In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Cardiac resynchronization therapy: left or non-left bundle branch block? That is the question

Session EHRA Essentials 4 You- ePublications

Speaker Ines Aguiar Ricardo

Event : EHRA Essentials 4 You 2020

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : ePublication

Authors : I Aguiar Ricardo (Lisbon,PT), A Nunes-Ferreira (Lisbon,PT), J Rigueira (Lisbon,PT), T Rodrigues (Lisbon,PT), N Cunha (Lisbon,PT), PS Antonio (Lisbon,PT), P Morais (Lisbon,PT), SC Pereira (Lisbon,PT), A Bernardes (Lisbon,PT), I Santos (Lisbon,PT), A Magalhaes (Lisbon,PT), H Neves (Lisbon,PT), FJ Pinto (Lisbon,PT), J De Sousa (Lisbon,PT), P Marques (Lisbon,PT)

I Aguiar Ricardo1 , A Nunes-Ferreira1 , J Rigueira1 , T Rodrigues1 , N Cunha1 , PS Antonio1 , P Morais1 , SC Pereira1 , A Bernardes1 , I Santos1 , A Magalhaes1 , H Neves1 , FJ Pinto1 , J De Sousa1 , P Marques1 , 1Santa Maria University Hospital/CHULN, CAML, CCUL, Lisbon School of Medicine, Universidade de Lisboa, Cardiology - Lisbon - Portugal ,



Cardiac resynchronization therapy (CRT) is associated with reduced mortality and improved quality of life in patients (pts) with low ejection fraction (EF) and conduction delays. Patients with left bundle branch block (LBBB) seem to be the ones who benefit the most from CRT and there is controversy about its efficacy in patients with non-LBBB.

To compare the prognostic impact and the response rate to CRT in patients with LBBB and non-LBBB.


Prospective single-center study of patients who implanted CRT between 2015 and 2019. Clinical, electrocardiographic and echocardiographic evaluations were made before CRT implant and between 6-12 months post-implant. Patients with EF elevation = 10% or left ventricle end-systolic volume (ESV) reduction = 15% were classified as responders. Patients with EF elevation = 20% or LV ESV reduction = 30% were classified as super-responders. All the parameters were compared between patients with or without LBBB. Prognostic impact of resynchronization therapy was evaluated by comparing total mortality using the Cox regression and Kaplan-Meier methods.


From 2015-2019, 566 CRTs were implanted (26.1% female, 72±10.2 years old, follow-up duration 18.9±15.8 months). From these patients, 59% had LBBB (69% males, mean age 71.6±10.8 years, 34.5% ischemic, EF < 30% in 65.5%). The cardiovascular risk factors and comorbidities were similar in both populations (with and without LBBB), except for diabetes which was more frequent in non-LBBB patients (33% vs 50.6%, p=0.007). Mean duration of QRS was similar between LBBB vs non-LBBB patients (163±19ms vs 160±22ms, p=NS) and baseline ejection fraction was also equivalent (29.8±13.6% vs 27.9±8.9%).

The prevalence of complications and surgical revisions were similar in both groups.

The response rate according to left ventricle remodelling criteria was higher in LBBB pts (65.9% vs 49.1%, p<0.05), but the super-responders were similar in both groups (32.5% vs 26.4% p=NS).

The 4-year survival rate of patients with LBBB and non-LBBB was similar (86.5% vs 85.3%).


In our population the response rate to CRT was higher in LBBB pts. However, and despite the actual controversy about the efficacy of CRT in non-LBBB, the long-term mortality was similar in patients with or without LBBB.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are